NF-kappa-B Decoy oligonucleotide - Anesiva

Drug Profile

NF-kappa-B Decoy oligonucleotide - Anesiva

Alternative Names: Avrina; NF-kappa-B Transcription Factor Decoy; NF-KB Decoy

Latest Information Update: 06 Mar 2014

Price : $50

At a glance

  • Originator Anesiva
  • Developer Transcription Factor Therapeutics
  • Class Anti-inflammatories; Antirheumatics; Oligonucleotides
  • Mechanism of Action NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atopic dermatitis; Inflammatory bowel diseases; Osteoarthritis; Rheumatoid arthritis

Most Recent Events

  • 01 Mar 2014 Discontinued - Preclinical for Rheumatoid arthritis in USA (Intra-articular)
  • 01 Mar 2014 Discontinued - Preclinical for Osteoarthritis in USA (Intra-articular)
  • 01 Mar 2014 Discontinued - Preclinical for Inflammatory bowel disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top